COMPUGEN LTD (CGEN)       1.12  -0.02 (-1.75%)

1.12  -0.02 (-1.75%)

IL0010852080 - Common Stock

COMPUGEN LTD1.12

NASDAQ:CGEN (12/7/2022, 1:24:50 PM)-0.02 (-1.75%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Life Sciences Tools & Services
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 11-14 2022-11-14/bmo Earnings (Next) 02-22 2023-02-22
Ins Owners N/A Inst Owners 25.46%
Market Cap 97.02M Shares 86.62M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 84.62
IPO 08-01 2000-08-01

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

CGEN Daily chart

Company Profile

Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. The firm focuses on infrastructure to discover drug targets and develop therapeutics. The firm is engaged in the research, development and commercialization of therapeutic and product candidates. The firm's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.

Company Info

COMPUGEN LTD

Azrieli Center, 26 Harokmim St. Bldg D

Holon 5885849

P: 97237658585.0

CEO: Anat Cohen-Dayag

Employees: 73

Website: http://www.cgen.com/

CGEN News

News Imagea day ago - Seeking AlphaCompugen COM701 in dual/triple combo shows promise in ovarian cancer patients in trial

Compugen (CGEN) said its drug COM701 in dual and triple combination with Bristol-Myers Squibb's (BMY) Opdivo (nivolumab) ± BMS-986207 (anti-TIGIT) showed preliminary durable...

News Image6 days ago - Compugen Ltd.Compugen's COM701 (anti-PVRIG) in Dual and Triple Combination Demonstrates Preliminary Anti-Tumor Activity and Immune Activation in Platinum Resistant Ovarian Cancer Patients

At the time of abstract data cutoff, COM701+ nivolumab + BMS-986207 (anti-TIGIT) demonstrated encouraging 20% overall response rate and 40% disease control...

News Image7 days ago - The Motley FoolWhy Shares of Compugen Rose 16.5% on Wednesday

Market factors and a company announcement helped the stock climb.

News Image8 days ago - Compugen Ltd.Compugen to Participate in the JMP Securities Hematology and Oncology Summit

/PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today...

News Image20 days ago - The Motley FoolWhy Shares of Compugen Jumped 17.86% on Thursday

The company is receiving a $7.5 milestone payment from AstraZeneca for the use of one of its therapies.

News Image23 days ago - The Motley FoolWhy Compugen Stock Crumbled Today

Investors indicated their displeasure with the company's recent fundamentals.

CGEN Twits

Here you can normally see the latest stock twits on CGEN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example